Opendata, web and dolomites

ENBIOSURF

Enzymatic production of a novel class of nonionic, mild and biobased surfactants

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ENBIOSURF" data sheet

The following table provides information about the project.

Coordinator
Enza Biotech AB 

Organization address
address: Kemicentrum
city: Lund
postcode: 221 00
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.enzabiotech.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-03-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Enza Biotech AB SE (Lund) coordinator 50˙000.00

Map

 Project objective

A completely new class of non-ionic, biobased and mild surfactants that have been shown to have a number of advantageous technical features compared with commercial alternatives, have been produced using a novel enzymatically catalysed process (patent pending). This project aims at investigating the feasibility of a more economical route of their production to expand their market potential. The novel group of surfactants consist of oligomeric alkyl glycosides with head-groups substantially larger than those already on the market. The biocatalytic process developed is the only way such surfactants can be produced, and they have for the first time ever been produced in amounts that have allowed for their features to be established. Their mild and technically superior features render them extremely attractive for replacing ethoxylated surfactants such as the polysorbates in pharmaceutical formulations, thereby solving the problems of allergies and side-effects associated with the formation of oxidation products including formaldehyde. The new class of surfactants will, if the production cost is reduced, also be very attractive for the cosmetics- and personal care markets including a large number of European cosmetics companies. The cosmetic sector has a large need for both replacing ethoxylated surfactants and introducing “green” ingredients that can be accepted under for instance the Cosmos standard, a European standard for organic and natural cosmetics. The mild and green features of the oligomeric alkyl glycosides make them very attractive for this sector. This project aims at investigating the bottle-necks for achieving a more economical process including type of raw material, re-use of material, conversion, downstream processing etc. This will prepare for scaling up and a larger market introduction which will be the aim for a project proposal for phase 2 funding, after which a partner deal including licensing and/or acquisition is expected.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ENBIOSURF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ENBIOSURF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More